Amcor (NYSE: AMCR) completed a 1-for-5 reverse stock split, effective with trading on a split-adjusted basis on January 16, 2026.
The split was approved by shareholders on November 6, 2025, and the memorandum of association amendment was filed on January 14, 2026. Amcor ordinary shares continue trading under AMCR on the NYSE with a new CUSIP G0250X149. CHESS Depositary Interests continue trading under AMC on a split-adjusted basis. Computershare is acting as exchange agent; registered U.S. shareholders and CDI holders have specified contact numbers for exchange questions. More details are available in Amcor's September 23, 2025 proxy and on its investor website.
Loading...
Loading translation...
Positive
Completed a 1-for-5 reverse split effective Jan 16, 2026
New NYSE CUSIP G0250X149 established for ordinary shares
Negative
Shares consolidated at a 1-for-5 ratio, which may reduce share count
Potentially lower liquidity due to split-adjusted trading (immediate effect)
Market Context
This announcement completes Amcor’s previously outlined 1-for-5 reverse stock split, following share...
Analysis
This announcement completes Amcor’s previously outlined 1-for-5 reverse stock split, following shareholder approval and the effective date set in December 2025. It is a largely mechanical step that consolidates shares while leaving recent fundamentals—such as strong Q1 results and reaffirmed fiscal 2026 guidance—unchanged. Investors may focus on how split-adjusted metrics are reported, any impacts on trading liquidity, and how this action fits alongside the company’s existing S-3ASR flexibility and recent governance decisions.
Key Figures
Chromium Xo price:$25,000Cell capture rate:80%Gene sensitivity uplift:40%+2 more
5 metrics
Chromium Xo price$25,000U.S. list price for single cell instrument
Cell capture rate80%GEM-X 3' assay maximum cell capture
Gene sensitivity uplift40%Higher gene sensitivity vs non-10x methods
Sequencing cost savings50%Potential savings vs non-10x methods
Target cost per sample$100Goal for high-performance single cell analysis per sample
Announced timing and access details for Q1 2026 results call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news with clearly positive fundamentals (earnings, sustainability progress) saw modestly positive price reactions, while the earlier reverse split announcement drew a small decline.
Recent Company History
Over the last few months, Amcor reported strong combined Q1 results with $5,745M net sales and $909M adjusted EBITDA, reaffirmed fiscal 2026 guidance, and raised its quarterly dividend. Sustainability reporting highlighted progress on circularity, emissions and recyclability, while innovation programs like Amcor Lift-Off targeted more sustainable packaging technologies. The prior 1-for-5 reverse split announcement on Dec 11, 2025 produced a modest -1.2% move, providing the key historical reference for today’s reverse split completion.
Key Terms
single cell analysis, spatial biology, sequencing, ffpe
4 terms
single cell analysismedical
"Designed to meet the needs of researchers who desire high-quality data on limited budgets, Chromium Xo offers an affordable entry point into routine, high-performance single cell analysis."
A laboratory method that examines individual cells one by one to measure their genes, proteins or activity, rather than averaging results across many cells. For investors, it matters because this fine-grained view can reveal hidden subpopulations, pinpoint more precise drug targets, improve diagnostic tests and reduce development risk—think of inspecting each brick in a wall to find the ones that need repair instead of judging the wall as a whole.
spatial biologymedical
"10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Chromium Xo,"
Spatial biology maps where different cells and molecules sit inside tissues, like a detailed city map showing not just who lives in a neighborhood but where every house and shop is located. For investors, those location details can reveal how diseases start and respond to treatments, guiding new drugs, diagnostics, and lab tools that can change clinical success rates and create commercial opportunities.
sequencingtechnical
"GEM-X technology also enables researchers to generate more usable reads to detect more genes with less sequencing, potentially saving more than 50% on sequencing costs"
Sequencing is the laboratory process that reads the exact order of the building blocks in DNA or RNA, like reading the letters in a book that make up a living organism’s instruction manual. For investors, sequencing matters because it powers diagnostics, drug discovery and personalized medicine — similar to how having a detailed map lets a company target opportunities more precisely, which can change revenue potential and regulatory risk.
ffpemedical
"upgrade to Chromium X to access the full breadth of the company's single cell portfolio, including assays for FFPE samples and immune profiling."
FFPE stands for formalin-fixed, paraffin-embedded, a standard laboratory method for preserving tissue samples by chemically fixing them and enclosing them in wax so they keep their structure over time. Think of it like embedding a pressed flower in wax to preserve its shape and details. For investors, FFPE matters because many diagnostic tests, drug development studies and biomarker analyses rely on these preserved samples; their quality and compatibility with laboratory assays affect clinical validation, regulatory approval and the commercial value of pathology and diagnostics products.
ZURICH, Jan. 15, 2026 /PRNewswire/ -- Amcor plc (NYSE: AMCR; ASX: AMC), a global leader in developing and producing responsible packaging solutions, announced today it has completed its previously announced 1-for-5 reverse stock split.
The reverse stock split was approved by Amcor shareholders at its annual general meeting of shareholders held on November 6, 2025. Amcor filed an amendment to its memorandum of association to effect the reverse stock split on January 14, 2026.
Amcor ordinary shares began trading on a split-adjusted basis on the New York Stock Exchange ("NYSE") today and shares continue to trade under the symbol "AMCR" with a new CUSIP number, which is G0250X 149. Amcor's CHESS Depositary Interests ("CDIs") continue to trade under the symbol "AMC" and are also now trading on a split-adjusted basis.
Amcor's transfer agent, Computershare, is acting as exchange agent for the reverse stock split. Registered U.S. shareholders who hold their shares directly may contact Computershare toll free at 1-866-526-3029 (within the U.S.), or at 1-617-668-3920. Holders of CDIs may contact Computershare toll free at 1300 850 505 (within Australia) or at +61 3 9415 4000 (outside of Australia). If you hold your shares with a broker, queries should be directed to your broker.
Additional information concerning the reverse stock split can be found in Amcor's definitive proxy statement filed with the Securities and Exchange Commission on September 23, 2025, as well as on Amcor's Investor Relations website, https://www.amcor.com/investors.
About Amcor
Amcor is the global leader in developing and producing responsible consumer packaging and dispensing solutions across a variety of materials for nutrition, health, beauty and wellness categories. Our global product innovation and sustainability expertise enables us to solve packaging challenges around the world every day, producing a range of flexible packaging, rigid packaging, cartons, and closures, that are more sustainable, functional and appealing for our customers and their consumers. We are guided by our purpose of elevating customers, shaping lives and protecting the future. Supported by a commitment to safety, over 75,000 people generate $23 billion in annualized sales from operations that span over 400 locations in more than 40 countries. NYSE: AMCR; ASX: AMC
